Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Akaolisa Samuel Eziokwu"'
Autor:
Leticia Varella, George Thomas Budd, Xuefei Jia, Halle C. F. Moore, Alberto J. Montero, Akaolisa Samuel Eziokwu, Jame Abraham, Megan L. Kruse
Publikováno v:
Breast Cancer Research and Treatment. 176:429-434
Real-world data are critical to demonstrate the reproducibility of evidence and external generalizability of randomized clinical trials. Palbociclib is an oral small-molecule inhibitor of cyclin-dependent kinases 4 and 6 that has been shown to improv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8cf3ebe90fa96d6ec43242567230644
https://doi.org/10.1007/s10549-019-05176-1
https://doi.org/10.1007/s10549-019-05176-1
Autor:
Alberto J. Montero, Halle C. F. Moore, Xuefei Jia, George Thomas Budd, Jame Abraham, Akaolisa Samuel Eziokwu, Leticia Varella, Megan L. Kruse
Publikováno v:
Clinical breast cancer. 21(3)
Background CDK4/6 inhibitors (CDK4/6i), in combination with aromatase inhibitors, are United States Food and Drug Administration-approved for the treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f43ec3be54ce4fbfef25ffe7fc2145c7
https://pubmed.ncbi.nlm.nih.gov/33189562
https://pubmed.ncbi.nlm.nih.gov/33189562
Publikováno v:
Leukemia & Lymphoma. 60:2337-2339
Pure red cell aplasia (PRCA) is characterized by normocytic normochromic anemia, severe reticulocytopenia, and a total absence or marked reduction of erythroid precursors in the bone marrow. It can...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::593eec37ff050376df8185d286bb268d
https://doi.org/10.1080/10428194.2019.1574007
https://doi.org/10.1080/10428194.2019.1574007
Publikováno v:
Cureus
A 24-year-old African-American man presented with malaise and low back pain and was found to have acute severe rhabdomyolysis followed by acute hemolysis. Glucose-6-phosphate dehydrogenase (G6PD) deficiency was suspected by the presence of blister ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f3605805c5160ea7b8873dc58a4275f
http://europepmc.org/articles/PMC5973499
http://europepmc.org/articles/PMC5973499
Autor:
Robert R. Lorenz, Shlomo A. Koyfman, Akaolisa Samuel Eziokwu, B. Matia, J. Ku, Brandon Prendes, Neil M. Woody, Eric Lamarre, Chandana A. Reddy, Joseph Scharpf, David J. Adelstein, Brian B. Burkey, Jessica L. Geiger, Nikhil P. Joshi
Publikováno v:
Journal of Clinical Oncology. 37:e17570-e17570
e17570 Background: IMRT for HNSCC limits exposure to critical nearby structures thereby reducing toxicities. Real world data on toxicities after long term follow-up post IMRT for HNSCC are lacking. This study assessed the incidence of late toxicities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aaf054e7873432b954b1e1d9641857b0
https://doi.org/10.1200/jco.2019.37.15_suppl.e17570
https://doi.org/10.1200/jco.2019.37.15_suppl.e17570
Autor:
George Thomas Budd, Alberto J. Montero, Xuefei Jia, Megan L. Kruse, Leticia Varella, Akaolisa Samuel Eziokwu, Halle C. F. Moore, Jame Abraham
Publikováno v:
Journal of Clinical Oncology. 37:e12538-e12538
e12538 Background: CDK inhibitors (CDKi), in combination with aromatase inhibitors (AI), are approved for the treatment of hormone receptor positive (HR+) Her2 negative metastatic breast cancer (MBC). The effectiveness of continuing CDKi beyond first
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d9bf2ffcfa02900bcae76c0ce727ccf
https://doi.org/10.1200/jco.2019.37.15_suppl.e12538
https://doi.org/10.1200/jco.2019.37.15_suppl.e12538
Autor:
Alberto J. Montero, Halle C. F. Moore, Megan L. Kruse, Jame Abraham, Xuefei Jia, Leticia Varella, George Thomas Budd, Akaolisa Samuel Eziokwu
Publikováno v:
Journal of Clinical Oncology. 36:e13034-e13034
e13034Background: Palbociclib (PA), a CDK4/CDK6 inhibitor, has been shown in clinical trials to prolong progression free survival (PFS) in HR+/Her-2 negative MBC when combined with an aromatase inh...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf0435d1d95bfb82a501e3debbb81dd4
https://doi.org/10.1200/jco.2018.36.15_suppl.e13034
https://doi.org/10.1200/jco.2018.36.15_suppl.e13034